← Leaderboards
Daniel J. Moore
Vanderbilt University
$2,401,640
Attributed
$2,401,640
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $625K · FY2008–25$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,401,640 · 8
By mechanism
R21$861,376 · 2
R01$625,035 · 2
K08$433,800 · 1
R56$173,000 · 1
R03$156,000 · 1
F32$152,429 · 1
Top collaborators
No co-investigators on record.
Most similar at Vanderbilt University
Same institution · by research overlap
- Richard M O'Brien$22,760,592
- Owen P McGuinness$19,104,126
- Christopher R Aiken$23,132,488
- Wenbiao Chen$6,468,374
- John Hughes Newman$11,268,781
Others in their field
Top investigators on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$493,822,581
- Barton F Haynes · Duke University$295,802,493
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$286,700,869
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$176,977,598
- Dan H. Barouch · Fred Hutchinson Cancer Center$122,734,499
Research focus
MediatingInsulin-Dependent Diabetes MellitusIsletPreventCellsImmuneBeta CellT-LymphocyteInsulinInbred Nod MiceInnovationChildImmune ToleranceAutoimmune DiseasesDiabetes MellitusB-LymphocytesSignal TransductionAmericanAutoimmune ProcessImmunityImmune SystemCell PhysiologyFunctional DisorderAutoimmunity
Grant awards (15)
Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes$339,060
R01 · FY2025 · DK · contact PI
Optimizing Stage 2 T1DM Management: Assessing the Impact of GLP-1Ra on Metabolic Outcomes in Patients Receiving Teplizumab$285,975
R01 · FY2025 · DK · contact PI
Disruption of Treg-dependent Tolerance by B lymphocytes in Islet Transplantation$173,000
R56 · FY2021 · DK · contact PI
The Contribution of B Lymphocyte to T1D Reversal by Imatinib$197,500
R21 · FY2017 · AI · contact PI
The Contribution of B Lymphocyte to T1D Reversal by Imatinib$237,000
R21 · FY2016 · AI · contact PI
High Throughput Identification of Treg Activating Molecules$194,600
R21 · FY2016 · AI · contact PI
High Throughput Identification of Treg Activating Molecules$232,276
R21 · FY2015 · AI · contact PI
Restoration of Immune Tolerance in Type 1 Diabetes$78,000
R03 · FY2014 · DK · contact PI
Harnessing B lymphocytes as Antigen-Specific Regulators of Islet Tolerance$144,600
K08 · FY2013 · DK · contact PI
Restoration of Immune Tolerance in Type 1 Diabetes$78,000
R03 · FY2013 · DK · contact PI
Harnessing B lymphocytes as Antigen-Specific Regulators of Islet Tolerance$144,600
K08 · FY2012 · DK · contact PI
Harnessing B lymphocytes as Antigen-Specific Regulators of Islet Tolerance$144,600
K08 · FY2011 · DK · contact PI
Intracellular Targeting of Proinflammatory Pathways to Ameliorate Type 1 Diabetes$40,393
F32 · FY2010 · DK · contact PI
Intracellular Targeting of Proinflammatory Pathways to Ameliorate Type 1 Diabetes$57,194
F32 · FY2009 · DK · contact PI
Intracellular Targeting of Proinflammatory Pathways to Ameliorate Type 1 Diabetes$54,842
F32 · FY2008 · DK · contact PI